Illumina Completes Acquisition of GenoLogics
News Sep 02, 2015
Illumina, Inc. has announced that it has completed the acquisition of GenoLogics Life Science Software Inc., a developer of industry leading laboratory information management systems (LIMS) for life sciences organizations.
"We look forward to working with the talented team at GenoLogics and to further integrate their life science software as part of the overall Illumina informatics solution," said Francis deSouza, President of Illumina. “Adopted by more than 120 genomic labs worldwide, GenoLogics’s Clarity LIMS software strengthens our industry leading portfolio of genetic analysis solutions.”
The completion of the acquisition demonstrates Illumina’s commitment to drive the adoption of sequencing in new markets and improve the genomic workflow.
GenoLogics’ Clarity LIMS™ software enables lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE